Lesson plan
Cenegermin
Cenegermin, sold under the brand name Oxervate, also known as recombinant human nerve growth factor, is a recombinant form of human nerve growth factor. Cenegermin is a peripherally selective agonist of the tropomyosin receptor kinase A (TrkA) and low-affinity nerve growth factor receptor (p75NTR). The most common side effects include eye pain and inflammation, increased lacrimation (watery eyes), pain in the eyelid and sensation of a foreign body in the eye. It was approved for medical use in the European Union in July 2017, and in the United States in 2018. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Article summary
Cenegermin, sold under the brand name Oxervate, also known as recombinant human nerve growth factor, is a recombinant form of human nerve growth factor. Cenegermin is a peripherally selective agonist of the tropomyosin receptor kinase A (TrkA) and low-affinity nerve growth factor receptor (p75NTR). The most common side effects include eye pain and inflammation, increased lacrimation (watery eyes), pain in the eyelid and sensation of a foreign body in the eye. It was approved for medical use in the European Union in July 2017, and in the United States in 2018. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.